Higher consumption of oily fish such as tuna and salmon or lean fish like cod and perch is associated with a reduced risk for disability progression in patients with multiple sclerosis (MS), a new ...

Physical activity was associated with a lower risk of disability progression in multiple sclerosis (MS), longitudinal data showed. Compared with low physical activity, the risk of confirmed disability ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

Racial and ethnic differences in the severity, prognosis, and mortality of multiple sclerosis (MS) have been the focus of intensifying research over the last decade, and emerging evidence suggests ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). The Phase 3 HERCULES ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS). The breakthrough research has the potential to ...

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...

Please provide your email address to receive an email when new articles are posted on . Adults either continued to receive ublituximab or switched from teriflunomide to ublituximab in this 3-year open ...